Cover Image
市場調查報告書

異位性皮膚炎:開發平台分析

Atopic Dermatitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232797
出版日期 內容資訊 英文 374 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎:開發平台分析 Atopic Dermatitis - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 374 Pages
簡介

異位性皮膚炎是皮膚變癢的發炎,也有慢性的症狀拖長,伴隨氣喘和花粉症。 症侯有紅色到帶茶色的灰色斑點,發癢,尤其是夜間變得厲害。有小小隆起的疙瘩,抓的話會有體液流出變成瘡痂,肥厚性的鱗狀皮膚,抓的話潰爛變敏感的皮膚等。

本報告提供異位性皮膚炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍
  • 異位性皮膚炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Abeome Corporation
  • Accolade Pharmaceuticals, LLC
  • AlbireoPharma
  • Almirall, S.A.
  • Amgen Inc.
  • Amorepacific Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaMar AB
  • AnaptysBio, Inc.
  • AnGes MG, Inc.
  • Aquinox Pharmaceuticals Inc.
  • arGEN-X BV
  • Blueberry Therapeutics Ltd
  • Brickell Biotech, Inc.
  • Celgene Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • 中外製藥
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Dr. August Wolff GmbH & Co. KG Arzneimittle
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Han Wha Pharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Immune Pharmaceuticals Inc.
  • Inflamalps SA
  • 日本煙草產業
  • Johnson & Johnson
  • Kineta, Inc.
  • LegoChem Biosciences, Inc
  • LEO Pharma A/S
  • Madam Therapeutics B.V.
  • MedImmune, LLC
  • NeoPharm Co., Ltd.
  • Novan, Inc.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • 大塚集團
  • Oxagen Limited
  • Pfizer Inc.
  • Pharis Biotec GmbH
  • Pharmedartis GmbH
  • Provectus Biopharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Signum Dermalogix, Inc
  • Spherium Biomed S.L.
  • sterna biologicals Gmbh & Co KG
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • SWITCH Biotech LLC
  • 武田藥品工業
  • Thesan Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Vicore Pharma AB
  • Vitae Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-3914
  • A-5425
  • AKP-11
  • ALX-101
  • AM-1030
  • AN-4161
  • ANB-020
  • apremilast
  • 異位性皮膚炎用Galectin-3抑制適體
  • AQX-1125
  • ARGX-112
  • ARN-077
  • baricitinib
  • BB-2702
  • BBI-2000
  • BBI-5000
  • bertilimumab
  • 異位性皮膚炎、皮膚炎用生技藥品
  • C-21
  • CBP-174
  • CBP-201
  • CCX-6239
  • CDE-001
  • Cis-Urocanic Acid
  • CNTO-7160
  • kobamamido
  • crisaborole
  • CT-101
  • CT-1x1
  • CT-1x2
  • CT-1x3
  • CT-327
  • CT-340
  • Cyclosporine
  • dalazatide
  • DMT-210
  • DRM-02
  • 異位性皮膚炎治療藥
  • 異位性皮膚炎用 TNFR-1拮抗劑
  • deyupirumabu
  • FB-825
  • fevipiprant
  • FIB-116
  • Furestem-AD
  • GBR-830
  • Histimex
  • HS-378
  • JTE-052
  • KPI-150
  • LCB-030110
  • lebrikizumab
  • LEKTI-6
  • LEO-32731
  • LEO-39652
  • mepolizumab
  • MLR-1130
  • mometasone furoate
  • 氣喘、線維症、異位性皮膚炎用 IL-25抑制單株抗體
  • 異位性皮膚炎用 IL-4/IL-13抑制單株抗體
  • 發炎性用腸道疾病、 異位性皮膚炎、大腸癌 Th22細胞/IL-22途徑標的單株抗體
  • N-oleoylethanolamine
  • nemolizumab
  • NPH-12
  • OC-000459
  • OC-2417
  • octenidine hydrochloride
  • OLX-103
  • omiganan pentahydrochloride
  • OPA-15406
  • P-10
  • PAC-14028
  • PDI-192
  • 異位性皮膚炎用 CX3CR1拮抗肽
  • 異位性皮膚炎用 TNFR-1拮抗肽
  • PH-10
  • PL-601
  • PMA-101R
  • PMA-201
  • PMA-411R
  • prednisone
  • PZ-235
  • Q-301
  • Qi-507
  • roflumilast
  • RTU-1096
  • RVT-501
  • S-414114
  • SB-011
  • SB-414
  • SIG-1311
  • SIG-1322
  • 異位性皮膚炎用 S1PR1調整藥
  • 異位性皮膚炎用小分子
  • SP-14019
  • SUN-0597
  • SWT-01113
  • SWT-05141
  • 免疫學、皮膚疾病、遺傳性疾病用激肽釋放酶抑制合成肽
  • tacrolimus
  • tezepelumab
  • tofacitinib
  • tralokinumab
  • ustekinumab
  • VTP-38543
  • WBI-1001
  • WOL-071007
  • XmAb-7195
  • YJC-10592
  • Zafi-1
  • ZPL-3893787
  • ZPL-5212372

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9069IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H1 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 8
  • List of Figures 10
  • Introduction 11
  • Global Markets Direct Report Coverage 11
  • Atopic Dermatitis - Overview 12
  • Atopic Dermatitis - Therapeutics Development 13
  • Pipeline Overview 13
  • Pipeline by Companies 14
  • Pipeline by Universities/Institutes 20
  • Products under Development by Companies 21
  • Products under Development by Universities/Institutes 28
  • Atopic Dermatitis - Therapeutics Assessment 29
  • Assessment by Target 29
  • Assessment by Mechanism of Action 33
  • Assessment by Route of Administration 37
  • Assessment by Molecule Type 39
  • Atopic Dermatitis - Companies Involved in Therapeutics Development 41
  • AbbVie Inc 41
  • Accolade Pharmaceuticals LLC 41
  • Albireo Pharma Inc 42
  • Almirall SA 42
  • Amgen Inc 43
  • Amorepacific Corp 43
  • AnaptysBio Inc 44
  • AnGes MG Inc 44
  • Antibiotx ApS 45
  • Avexxin AS 45
  • Blueberry Therapeutics Ltd 46
  • Brickell Biotech Inc 46
  • Celgene Corp 47
  • Cell Medica Ltd 47
  • Cellceutix Corp 48
  • ChemoCentryx Inc 48
  • ChironWells GmbH 49
  • Chugai Pharmaceutical Co Ltd 49
  • Clevexel Pharma SA 50
  • Curapel Ltd 50
  • Cutanea Life Sciences Inc 51
  • Dermala Inc 51
  • Dr. August Wolff GmbH & Co KG Arzneimittle 52
  • Eli Lilly and Company 52
  • Exicure Inc 53
  • F. Hoffmann-La Roche Ltd 53
  • Foamix Pharmaceuticals Ltd 54
  • Fountain Biopharma Inc 54
  • Galapagos NV 55
  • Galectin Therapeutics Inc 55
  • GlaxoSmithKline Plc 56
  • Glenmark Pharmaceuticals Ltd 56
  • Grupo Ferrer Internacional SA 57
  • GTx Inc 57
  • Han Wha Pharma Co Ltd 58
  • HanAll Biopharma Co Ltd 58
  • Heptares Therapeutics Ltd 59
  • Herantis Pharma Plc 59
  • iCo Therapeutics Inc. 60
  • Immune Pharmaceuticals Inc 60
  • Incyte Corp 61
  • Inflamalps SA 61
  • Japan Tobacco Inc 62
  • Kang Stem Biotech Co Ltd 62
  • KPI Therapeutics Inc 63
  • LEO Pharma A/S 63
  • Madam Therapeutics BV 64
  • MedImmune LLC 64
  • NeoPharm Co Ltd 65
  • Novan Inc 65
  • Novartis AG 66
  • Orbis Biosciences Inc 66
  • Otsuka Holdings Co Ltd 67
  • Oxagen Ltd 67
  • Pfizer Inc 68
  • Pharis Biotec GmbH 68
  • Pharmedartis GmbH 69
  • Provectus Biopharmaceuticals Inc 69
  • Qurient Co Ltd 70
  • Realm Therapeutics Plc 70
  • Regeneron Pharmaceuticals Inc 71
  • Roivant Sciences Ltd 71
  • Signum Biosciences Inc 72
  • Signum Dermalogix Inc 72
  • Spherium Biomed SL 73
  • sterna biologicals Gmbh & Co KG 73
  • Sun Pharma Advanced Research Company Ltd 74
  • SWITCH Biotech LLC 74
  • Thesan Pharmaceuticals Inc 75
  • Torrent Pharmaceuticals Ltd 75
  • Trevi Therapeutics Inc 76
  • Valeant Pharmaceuticals International Inc 76
  • Vicore Pharma AB 77
  • Vitae Pharmaceuticals Inc 77
  • VivaCell Biotechnology Espana SL 78
  • Xencor Inc 78
  • Zhejiang I-Biological Technology Co Ltd 79
  • Atopic Dermatitis - Drug Profiles 80
  • A-3914 - Drug Profile 80
  • A-5425 - Drug Profile 81
  • AKP-11 - Drug Profile 82
  • Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 84
  • ALX-101 - Drug Profile 85
  • AMG-0101 - Drug Profile 86
  • Anatabine - Drug Profile 88
  • ANB-020 - Drug Profile 91
  • Antisense Oligonucleotide to Antagonize IL-4RA for Atopic Dermatitis - Drug Profile 93
  • apremilast - Drug Profile 94
  • Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 106
  • ARN-077 - Drug Profile 107
  • AVX-001 - Drug Profile 108
  • AZT-01 - Drug Profile 110
  • B-244 - Drug Profile 111
  • baricitinib - Drug Profile 113
  • BB-2702 - Drug Profile 123
  • BBI-2000 - Drug Profile 124
  • BBI-5000 - Drug Profile 125
  • bertilimumab - Drug Profile 126
  • betamethasone valerate - Drug Profile 130
  • Biologic for Atopic Dermatitis - Drug Profile 131
  • Biologic for Atopic Dermatitis and Eczema - Drug Profile 132
  • brilacidin tetrahydrochloride - Drug Profile 133
  • BTX-1204 - Drug Profile 144
  • C-21 - Drug Profile 145
  • CBP-174 - Drug Profile 148
  • CBP-201 - Drug Profile 149
  • CCX-6239 - Drug Profile 150
  • CDE-001 - Drug Profile 151
  • Cis-Urocanic Acid - Drug Profile 152
  • cobamamide - Drug Profile 154
  • CT-101 - Drug Profile 156
  • CT-103 - Drug Profile 157
  • CVXL-0074 - Drug Profile 158
  • cyclosporin - Drug Profile 159
  • cyclosporine - Drug Profile 160
  • dalazatide - Drug Profile 161
  • DMT-210 - Drug Profile 166
  • Drug for Atopic Dermatitis - Drug Profile 168
  • Drug for Atopic Dermatitis - Drug Profile 169
  • dupilumab - Drug Profile 170
  • FB-825 - Drug Profile 179
  • fevipiprant - Drug Profile 180
  • FIB-116 - Drug Profile 182
  • FM-1202 - Drug Profile 183
  • Furestem-AD - Drug Profile 184
  • GBR-830 - Drug Profile 185
  • GLPG-2534 - Drug Profile 186
  • GRMD-02 - Drug Profile 187
  • GSK-3772847A - Drug Profile 200
  • Gtx-186 - Drug Profile 201
  • Histimex - Drug Profile 202
  • house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile 203
  • HS-378 - Drug Profile 204
  • IDP-124 - Drug Profile 205
  • INV-25 - Drug Profile 206
  • INV-88 - Drug Profile 207
  • JTE-052 - Drug Profile 208
  • K-1032 - Drug Profile 209
  • KPI-150 - Drug Profile 210
  • lebrikizumab - Drug Profile 211
  • LEKTI-6 - Drug Profile 215
  • LP-0058 - Drug Profile 216
  • LP-0108 - Drug Profile 217
  • LP-0145 - Drug Profile 218
  • LP-0155 - Drug Profile 219
  • MEDI-9314 - Drug Profile 220
  • mepolizumab - Drug Profile 221
  • MLR-1130 - Drug Profile 227
  • mometasone furoate - Drug Profile 228
  • Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 229
  • Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 230
  • MOR-106 - Drug Profile 231
  • MSB-01 - Drug Profile 233
  • nalbuphine hydrochloride ER - Drug Profile 234
  • nemolizumab - Drug Profile 238
  • niclosamide - Drug Profile 240
  • NPB-311 - Drug Profile 242
  • NPH-12 - Drug Profile 243
  • OC-2417 - Drug Profile 244
  • octenidine hydrochloride - Drug Profile 245
  • OLX-103 - Drug Profile 246
  • omiganan pentahydrochloride - Drug Profile 247
  • OPA-15406 - Drug Profile 250
  • P-10 - Drug Profile 252
  • P-148 - Drug Profile 253
  • PAC-14028 - Drug Profile 254
  • Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 256
  • Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 257
  • PF-04965842 - Drug Profile 258
  • PF-06817024 - Drug Profile 259
  • PH-10 - Drug Profile 260
  • PL-601 - Drug Profile 263
  • PMA-101R - Drug Profile 264
  • PMA-201 - Drug Profile 265
  • PMA-411R - Drug Profile 266
  • PR-022 - Drug Profile 267
  • prednisone - Drug Profile 269
  • PZ-235 - Drug Profile 270
  • ruxolitinib phosphate - Drug Profile 271
  • RVT-201 - Drug Profile 286
  • RVT-501 - Drug Profile 287
  • SB-011 - Drug Profile 289
  • SB-414 - Drug Profile 290
  • secukinumab - Drug Profile 291
  • SIG-1322 - Drug Profile 305
  • SIG-1451 - Drug Profile 306
  • Small Molecule for Atopic Dermatitis - Drug Profile 307
  • Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 308
  • Small Molecules for Atopic Dermatitis - Drug Profile 309
  • Small Molecules for Atopic Dermatitis - Drug Profile 310
  • Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 311
  • SNA-120 - Drug Profile 312
  • SNA-125 - Drug Profile 315
  • SUN-0597 - Drug Profile 316
  • SWT-01113 - Drug Profile 318
  • SWT-05141 - Drug Profile 319
  • Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 320
  • tacrolimus - Drug Profile 321
  • tezepelumab - Drug Profile 322
  • tralokinumab - Drug Profile 324
  • upadacitinib tartrate - Drug Profile 327
  • VTP-38543 - Drug Profile 330
  • WBI-1001 - Drug Profile 332
  • WOL-071007 - Drug Profile 334
  • XmAb-7195 - Drug Profile 335
  • YJC-10592 - Drug Profile 337
  • Zafi-1 - Drug Profile 338
  • zafirlukast - Drug Profile 339
  • zileuton - Drug Profile 340
  • ZPL-389 - Drug Profile 341
  • ZPL-521 - Drug Profile 343
  • Atopic Dermatitis - Dormant Projects 344
  • Atopic Dermatitis - Discontinued Products 350
  • Atopic Dermatitis - Product Development Milestones 351
  • Featured News & Press Releases 351
  • Appendix 364
  • Methodology 364
  • Coverage 364
  • Secondary Research 364
  • Primary Research 364
  • Expert Panel Validation 364
  • Contact Us 364
  • Disclaimer 365

List of Tables

  • Number of Products under Development for Atopic Dermatitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Atopic Dermatitis - Pipeline by AbbVie Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2017
  • Atopic Dermatitis - Pipeline by Albireo Pharma Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Almirall SA, H1 2017
  • Atopic Dermatitis - Pipeline by Amgen Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Amorepacific Corp, H1 2017
  • Atopic Dermatitis - Pipeline by AnaptysBio Inc, H1 2017
  • Atopic Dermatitis - Pipeline by AnGes MG Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Antibiotx ApS, H1 2017
  • Atopic Dermatitis - Pipeline by Avexxin AS, H1 2017
  • Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Celgene Corp, H1 2017
  • Atopic Dermatitis - Pipeline by Cell Medica Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Cellceutix Corp, H1 2017
  • Atopic Dermatitis - Pipeline by ChemoCentryx Inc, H1 2017
  • Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2017
  • Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Clevexel Pharma SA, H1 2017
  • Atopic Dermatitis - Pipeline by Curapel Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Cutanea Life Sciences Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Dermala Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
  • Atopic Dermatitis - Pipeline by Eli Lilly and Company, H1 2017
  • Atopic Dermatitis - Pipeline by Exicure Inc, H1 2017
  • Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Fountain Biopharma Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Galapagos NV, H1 2017
  • Atopic Dermatitis - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Atopic Dermatitis - Pipeline by GTx Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Han Wha Pharma Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H1 2017
  • Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H1 2017
  • Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Incyte Corp, H1 2017
  • Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2017
  • Atopic Dermatitis - Pipeline by Japan Tobacco Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2017
  • Atopic Dermatitis - Pipeline by Madam Therapeutics BV, H1 2017
  • Atopic Dermatitis - Pipeline by MedImmune LLC, H1 2017
  • Atopic Dermatitis - Pipeline by NeoPharm Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Novan Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Novartis AG, H1 2017
  • Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Oxagen Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Pfizer Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2017
  • Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2017
  • Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Qurient Co Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Realm Therapeutics Plc, H1 2017
  • Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Roivant Sciences Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Signum Biosciences Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Spherium Biomed SL, H1 2017
  • Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017
  • Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2017
  • Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Atopic Dermatitis - Pipeline by Trevi Therapeutics Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Vicore Pharma AB, H1 2017
  • Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals Inc, H1 2017
  • Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
  • Atopic Dermatitis - Pipeline by Xencor Inc, H1 2017
  • Atopic Dermatitis - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Atopic Dermatitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Atopic Dermatitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top